|
 |
polifeprosan 20 with carmustine implantThis page contains recent news articles, when available, and an overview of polifeprosan 20 with carmustine implant but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.Gliadel Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ... Free with registration - PR Newswire - AccessMyLibrary.com Gliadel(R) Wafer Clinical Data Presented At Society For Neuro... - Nov 21, 2006 Gliadel Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ... Medical News Today - Medical News Today (press release) MGI PHARMA Announces Results from Study Involving the Dual … - Jan 18, 2008 Gliadel(R) (polifeprosan 20 with carmustine implant) Wafer is indicated in patients with newly diagnosed high-grade malignant glioma as an adjunct to ... Genetic Engineering News - Genetic Engineering News (press release) Gliadel(R) Wafer Demonstrates Long-Term Survival Benefit for Patients... - Mar 8, 2006 Gliadel Wafer (polifeprosan 20 with carmustine implant) is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, and is indicated in ... Free with registration - Business Wire - AccessMyLibrary.com Guilford Pharmaceuticals Reports 2005 First Quarter Results. - May 9, 2005 Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... $4.95 - PR Newswire - ECNext Guilford Pharmaceuticals Reports 2004 Year-End Financial Results. - Mar 1, 2005 Revenues for GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) increased $8.5 million, or 44%, to $27.7 million in 2004 compared to $19.2 million ... $4.95 - PR Newswire - ECNext Guilford Pharmaceuticals Reports 2005 Second Quarter Results. - Aug 8, 2005 This was largely attributable to GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant) net product revenue, which increased by approximately 20% to ... $4.95 - PR Newswire - ECNext Eisai Gaining Cancer Portfolio In $3.9B MGI Acquisition - Dec 11, 2007 ...for myelodysplastic syndromes (MDS); Gliadel Wafer (polifeprosan 20 with carmustine implant), for malignant gliomas; Hexalen (altretamine), ... BioWorld Online - BioWorld Online Guilford Pharmaceuticals Stockholders Vote to Approve MGI PHARMA … - Sep 29, 2005 Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... $4.95 - PR Newswire - ECNext Press Release: Guilford Pharmaceuticals Stockholders Vote to Approve ... - Sep 29, 2005 Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... Pay-Per-View - PR Newswire - HighBeam Research Press Release: Gliadel(R) Wafer Clinical Data Presented at Society... - Nov 20, 2006 ...today summarized interim results from a phase 2 combination study of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in patients with ... Pay-Per-View - PR Newswire - HighBeam Research Helsinn and MGI Pharma announce sNDA for ALOXI Capsules accepted … - Mar 1, 2008 ...hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... presseportal.ch Data from Investigator-Sponsored Trial of Oncophage(R) Cancer Vaccine... - Apr 16, 2007 Dr. Brem is a developer of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant, MGI Pharma), the first approved local therapy for glioma. ... Genetic Engineering News - Genetic Engineering News (press release) Top stories, Leaders speak, Company News, Sector News, Market talk, … - Dec 3, 2008 ...approved product GLIDEL (polifeprosan 20 with carmustine implant) Wafer for the treatment of newly diagnosed high-grade malignant gliomas and recurrent ... India Infoline.com MGI PHARMA Reports First Quarter 2007 Financial Results. - Apr 18, 2007 Sales of Gliadel([R]) Wafer (polifeprosan 20 with carmustine implant) were $9.7 million for the first quarter of 2007, compared to $9.7 million in the first ... Free with registration - Business Wire - AccessMyLibrary.com Reports Activity for MGI PHARMA INC. - Oct 19, 2006 ...and the inclusion of sales of Gliadel Wafer (polifeprosan 20 with carmustine implant) following the 2005 acquisition of Guilford Pharmaceuticals Inc. ... Free with registration - M2 Presswire - AccessMyLibrary.com MGI PHARMA and HELSINN Announce sNDA for Aloxi Capsules … - Jan 3, 2008 ...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Announces Aquavan NDA Accepted for Review by US … - Dec 17, 2007 ...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) Novel glioblastoma therapy holds promise - Jan 21, 2008 Treating patients who have recurrent glioblastoma multiforme with both Gliadel® Wafer (polifeprosan 20 with carmustine implant) and radioactive seeds ... Pharmacy Europe MGI PHARMA Announces Commercial Availability of Dacogen(TM) ( … - May 26, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... RedOrbit MGI PHARMA Issues Statement - Nov 29, 2007 ...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA And SuperGen Provide Regulatory Status Updates For … - Nov 15, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... RedOrbit Company Profile for MGI PHARMA, INC. - Apr 16, 2008 MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) ... businesswire.com MGI PHARMA to Present at the UBS Global Life Sciences Conference. - Sep 19, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial … - Feb 7, 2007 ...launch of Dacogen(R) (decitabine) for Injection and incorporation of a full year of sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant). ... Genetic Engineering News - Genetic Engineering News (press release) Guilford Pharmaceuticals Announces Phase III AQUAVAN(R) Trial Meets … - Mar 24, 2005 Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... Free with registration - PR Newswire - AccessMyLibrary.com MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Mar 4, 2008 ...hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com MGI Paying $45M Up Front For Thrombocytopenia Drug - Aug 30, 2007 ...and Gliadel Wafer (polifeprosan 20 with carmustine implant) for malignant glioma. The company had a net income $11.1 million, or 13 cents per share, ... BioWorld Online - BioWorld Online Guilford Pharmaceuticals: AGGRASTAT(R) Injection Clinical Data … - Mar 8, 2005 Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... RedOrbit MGI PHARMA REPORTS FIRST QTR '06 TOTAL REVENUE OF $78.2 … - Jun 1, 2006 Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) totaled $9.7 million for the first quarter of 2006 compared to $7.3 million for the ... Free with registration - Biotech Financial Reports - AccessMyLibrary.com Positive data on MGI Pharma's Gliadel. - Jan 28, 2008 ...(GBM) with both MGI Pharma's Gliadel Wafer (polifeprosan 20 with carmustine implant) and radioactive seeds (iodine-125) at the time of tumor resection, ... Free with registration - Pharma Marketletter - AccessMyLibrary.com Dacogen(TM) (Decitabine) for Injection Receives US Orphan Drug … - Aug 10, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted … - Jul 9, 2007 ...hydrochloride) Injection, Dacogen® (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... RedOrbit Guilford Mulls Dosing Plan For Phase III With Aquavan - Mar 28, 2005 Guilford has two marketed products - Gliadel Wafer, which is polifeprosan 20 with carmustine implant for brain cancer, and Aggrastat (tirofiban ... BioWorld Online - BioWorld Online MGI PHARMA First Quarter 2006 Financial Results Conference Call to Be... - Apr 19, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Completes Acquisition of Guilford Pharmaceuticals. - Oct 3, 2005 Gliadel (polifeprosan 20 with carmustine implant) Wafer is a biodegradable wafer containing the chemotherapy agent carmustine, or BCNU, approved for the ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA To Present at The BMO Capital Markets 7th Annual Focus … - Nov 27, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Receives Approvable Letter for Saforis(TM) (Glutamine) … - Oct 12, 2006 ...hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com USA pharma: FDA approves Eisai sedative in limited setting - Dec 16, 2008 Aquavan was one of the top drugs in Guilford's pipeline, along with the marketed cancer drug Gliadel Wafer (polifeprosan 20 with carmustine implant). ... $34.00 - EIU Country Analysis - Alacra Store MGI PHARMA Summarizes Data Presented at the 2007 American Society … - Jun 4, 2007 Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) was the subject of two posters with one detailing the impact of multimodal therapy that included ... Genetic Engineering News - Genetic Engineering News (press release) Guilford Pharmaceuticals Restarts AQUAVAN(R) Clinical Development … - Apr 21, 2005 Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... RedOrbit MGI PHARMA To Present at the Bear Stearns 19th Annual Healthcare … - Sep 5, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the Cowen and Company 27th Annual … - Mar 8, 2007 ...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere MGI PHARMA Third Quarter 2005 Financial Results Conference Call to … - Oct 19, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com MGI PHARMA Recognized for Innovation & Growth. - Nov 2, 2006 ...hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Aquavan(R) (Fospropofol Disodium) Injection Data Presented at … - May 23, 2007 Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Company Profile Report - Jan 26, 2008 Alkylating Agents. Nitrosoureas. Products:. Gliadel Wafer (Polifeprosan 20 With Carmustine Implant). Phase I/Phase II Clinical Stage Products. Products: ... $50.00 - Revere Reports - Revere GSW Worldwide to Lead Saforis(TM) Launch Campaign for MGI PHARMA … - Nov 17, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - PR Newswire - AccessMyLibrary.com MGI PHARMA Updates Outlook for First Quarter - Apr 13, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA Announces Publication of Phase 3 Data for Saforis(TM) ( … - Jan 17, 2007 ...hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere Dacogen(TM) (Decitabine) Injection Complete Response Accepted for … - Dec 15, 2005 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - PR Newswire - AccessMyLibrary.com MGI PHARMA UNVEILS DACOGEN (DECITABINE) FOR INJECTION. - Jul 1, 2006 ...hydrochloride) Injection, Dacogen(tm) (decitabine) for Injection and Gliadel (r) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Biotech Business - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere MGI PHARMA to Present at the JP Morgan 25th Annual Healthcare … - Jan 3, 2007 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA To Present at the 2006 UBS Global Specialty … - Apr 17, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Announces Publication of Phase 3 Data for Dacogen(TM) ( … - Apr 18, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Summarizes Clinical Data Presented at American Society … - Jun 5, 2006 Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) presentations made during the 2006 American ... RedOrbit MGI PHARMA To Present at the Lehman Brothers 9th Annual Global … - Mar 3, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Dr. Gerard T. Kennealey Joins MGI PHARMA as Senior Vice President, … - May 25, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA To Present at the Baird 2006 Growth Stock Conference - May 10, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com MGI PHARMA To Present at the Bank of America Specialty … - Aug 3, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25, … - Jul 25, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com Dr. James Armitage Appointed to MGI PHARMA Board of Directors. - Jul 26, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com AkaRx and MGI PHARMA Announce Closing of Development and … - Oct 11, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection, and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Appoints William F. Spengler As CFO. - Apr 24, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Investment Alert for HSXI! June 27, 2006. - Jun 27, 2006 Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) presentations made during the 2006 American ... Free with registration - M2 Presswire - AccessMyLibrary.com MGI PHARMA Fourth Quarter and Year End 2006 Financial Results … - Feb 7, 2007 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) MGI PHARMA To Present at the Baird 2006 Growth Stock Conference. - May 4, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25, … - Jul 19, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Third Quarter 2007 Financial Results Conference Call to … - Oct 17, 2007 ...hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com Notice of Conversion Right for Senior Subordinated Convertible Notes ... - Dec 26, 2007 ...hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Genetic Engineering News - Genetic Engineering News (press release) Advanced Drug Delivery Systems: New Development, New Technologies - Oct 1, 2006 ...eg, the acquisition of Guilford Pharmaceuticals by MGI Pharma, which added Gliadel Wafer (polifeprosan 20 with carmustine implant) to its portfolio. ... MarketResearch.com MGI PHARMA Announces Change to Presentation Time at the Merrill … - Sep 19, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA to Present at the Bank of America Healthcare Conference. - May 24, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Third Quarter 2007 Financial Results Conference Call to … - Oct 10, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA First Quarter 2007 Financial Results Conference Call to Be... - Apr 11, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Third Quarter 2006 Financial Results Conference Call to … - Oct 18, 2006 ...hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter … - Dec 31, 2006 Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) were $8.5 million for the fourth quarter of 2005. Total costs and expenses increased to ... businesswire.com MGI PHARMA Fourth Quarter and Year End 2005 Financial Results … - Feb 8, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... businesswire.com Company Profile for MGI PHARMA, INC.(Company overview) - Sep 1, 2006 ...hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com MGI PHARMA Reports First Quarter 2006 Financial Results; First... - May 15, 2006 Sales of Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) totaled $9.7 million for the first quarter of 2006 compared to $7.3 million for the ... businesswire.com MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical … - Sep 12, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Rebecca Dop Completes Certified Trade Show Marketer (CTSM) … - Mar 21, 2007 Aloxi® (palonosetron hydrochloride) Injection, Dacogen ™ (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine implant) Wafer in the US. Exhibitor Online MGI PHARMA First Quarter 2006 Financial Results Conference Call to Be... - Apr 13, 2006 MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... Free with registration - Business Wire - AccessMyLibrary.com Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere MGI PHARMA to Present at the UBS Global Life Sciences Conference.( … - Sep 18, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - Business Wire - ECNext Guilford Pharmaceuticals to Host Webcast Outlining New Corporate … - Apr 5, 2005 Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, ... $4.95 - PR Newswire - ECNext MGI PHARMA to Present at the Bear Stearns 20th Annual Healthcare … - Sep 4, 2007 ...hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - Business Wire - ECNext Merger and Acquisition Scenario - Jan 26, 2008 Salagen (Pilocarpine Hydrochloride); Dacogen (Decitabine); Gliadel Wafer (Polifeprosan 20 With Carmustine Implant); Irofulven (Hydroxymethylacylfulvene) ... $250.00 - Revere Reports - Revere MOGN Shares Trade Up 20% on Buyout. - Dec 10, 2007 ...hydrochloride) Injection, Dacogen (decitabine) for Injection, and Gliadel Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - M2 Presswire - ECNext MGI PHARMA Reports Third Quarter 2006 Financial Results. - Oct 18, 2006 ...and the inclusion of sales of Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) following the 2005 acquisition of Guilford Pharmaceuticals Inc. ... $4.95 - Business Wire - ECNext MGI PHARMA to Present at the Lazard Capital Markets Third Annual Life... - Nov 20, 2006 ...hydrochloride) Injection, Dacogen[TM] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - Business Wire - ECNext MGI Submits NDA Seeking FDA Clearance For Saforis. - Apr 14, 2006 Also among the company's oncology products is the Gliadel Wafer (polifeprosan 20 with carmustine implant), which is sold for high-grade malignant gliomas. ... Pay-Per-View - BIOWORLD Today - Factiva, from Dow Jones WallStreetGrapevine.com "Spotlight" Alert - PECB, GLFD, AMGN - Jan 28, 2005 Presently, Guilford markets two commercial products, GLIADEL Wafer (polifeprosan 20 with carmustine implant), for the treatment of certain types of brain ... $4.95 - M2 Presswire - ECNext Guilford loses 20% of workforce over Gliadel.(pharmaceutial industry)(... - Jun 6, 2005 Gliadel Wafer (polifeprosan 20 with carmustine implant), and the clinical development of its novel hypnotic, Aquavan Injection (GPI 15715), ... $4.95 - Pharma Marketletter - ECNext MGI PHARMA and Guilford Pharmaceuticals Announce Expiration of the … - Sep 1, 2005 Presently, Guilford markets two commercial products, Gliadel(R) wafer (polifeprosan 20 with carmustine implant), for the treatment of high grade malignant ... $4.95 - Business Wire - ECNext MGI PHARMA and HELSINN HEALTHCARE SA Announce Patent … - Feb 13, 2007 Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - Business Wire - ECNext MGI PHARMA and HELSINN Announce Submission of Supplemental … - Oct 29, 2007 Dacogen([R]) (decitabine) for Injection, and Gliadel([R]) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... $4.95 - Business Wire - ECNext |
|
Health Home | Conditions | Cancer | Medications | Surgery | Vaccines The Cancer News Network
COPYRIGHT 2009 CANCERNEWSNETWORK | Privacy |